N@N

Signalife, Inc.: Heart Tronics to Screen Every U.S. Citizen With F-100 ECG Monitor

^{Published on 2008-11-25 08:06:07 - Market Wire}
 

LOS ANGELES, CALIFORNIA--(Marketwire - Nov. 25, 2008) - Heart Tronics, Inc., fka Signalife, Inc. (OTCBB:SGAL) announced today that - with the help and assistance of the public and private sectors - the Company intends to begin a nationwide "sweep" to screen every man, woman and child in the United States using the revolutionary Fidelity 100 ECG heart monitor. The screenings are expected to begin in January, 2009 and to conclude at the Super Bowl in 2012.

The Company will issue additional news as this major and unparalleled initiative moves forward. "We are thankful to the various public and private agencies that are already supporting this initiative, which will save lives as well as billions of dollars already needlessly spent every year on the care and treatment of cardiovascular disease," said Company CEO Willie Gault.

About Heart Tronics, Inc.

Heart Tronics, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. The Company uses its patented signal technology to design and develop medical devices - two of which are FDA-cleared - as well as therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Heart Tronics, Inc. is publicly traded OTC Bulletin Board and the Pink Sheets under the symbol SGAL. The website for the company is [ http://www.HeartTronics.com ]. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Heart Tronics' actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Heart Tronics' technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Heart Tronics' technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Heart Tronics' technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring, the compliance with purchase orders, payment for parts making up orders receiving by the Company and other biomedical devices incorporating Heart Tronics' technology. Additionally, Heart Tronics - in its prior name (Signalife) - has been sued in various class action lawsuits and has filed a lawsuit against alleged naked short sellers (and others, including the plaintiff's counsel in one class action matter), some of whom have since gone out of business for alleged naked short selling and other risky derivatives trading. These matters may negatively impact the Company or - possibly - may have the reverse impact. The Company and certain of its agents and prior agents are represented in defense of the class action lawsuits - and perhaps in other matters from time to time - by the national law firm of Akin Gump Strauss Hauer & Feld LLP with respect to these matters. While the Company believes these class action lawsuits lack merit and may be frivolous, the presence of the matters creates an obvious risk to the Company. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Heart Tronics' filings with the Securities and Exchange Commission.